Key result
FSHD-MPA accurately discriminated between FSHD patients and healthy individuals, distinguished FSHD1 from FSHD2, and showed a strong correlation between methylation level and clinical severity.
Why the study?
Genetic diagnosis of facioscapulohumeral muscular dystrophy remains challenging due to incomplete penetrance, epistatic effects, and limitations of conventional testing in predicting clinical severity.
Does FSHD-MPA accurately determine epigenetic parameters to diagnose and predict disease severity in patients with facioscapulohumeral muscular dystrophy compared to conventional genetic testing?
Cohort (n=148)
Does FSHD-MPA accurately determine epigenetic parameters to diagnose and predict disease severity in patients with facioscapulohumeral muscular dystrophy compared to conventional genetic testing?
FSHD-MPA is a powerful diagnostic tool that uses epigenetic parameters to accurately determine disease status and severity in facioscapulohumeral muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
May support FSHD diagnosis and subtyping; leaves open prospective validation before clinical adoption.
Erdmann et al. (2022) conducted a cohort in Facioscapulohumeral muscular dystrophy (FSHD) (n=148). High-throughput methylation profile analysis (FSHD-MPA) vs. Conventional genetic testing was evaluated on Discrimination between FSHD patients and healthy individuals, and correlation of methylation level with clinical severity. FSHD-MPA accurately discriminated between FSHD patients and healthy individuals, distinguished FSHD1 from FSHD2, and showed a strong correlation between methylation level and clinical severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: